Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $27 Price Target
Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $27 Price Target
坎託·菲茨傑拉德重申增持 Catalyst Pharmicals,維持27美元的目標股價
Cantor Fitzgerald analyst Charles Duncan reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight and maintains $27 price target.
坎託·菲茨傑拉德分析師查爾斯·鄧肯重申了Catalyst Pharmicals(納斯達克股票代碼:CPRX)的增持,並維持27美元的目標股價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。